The market accounts for nearly 60% of the anti-breast cancer drug TOP5 manufacturers competitive landscape perspective

Breast cancer is one of the major diseases that endanger women's health, and it has been the first kind of disease with the highest incidence of malignant tumors in women for many years. Statistics show that in the past 10 years, with the rapid development of global industrialization, as well as the aging of the population and people pay great attention to medical screening, malignant tumor incidence statistics have more than doubled.
breast cancer treatment is surgical treatment combined with chemotherapy and radiotherapy, with the emergence of new targeted treatment drugs, patients also have more options.100 billion yuan anti-tumor market
According to the "China's urban public hospital chemical terminal monitoring and analysis system" (HDM system) data, in 2015 urban public hospitals, county-level public hospitals, urban communities, township hospitals, brick-and-mortar pharmacies and online shops three terminals 6 major market anti-tumor drugs reached 95 billion yuan, a year-on-year growth rate of 13.53 percent. It is conservatively predicted that the anti-tumor market in China's three major terminals will reach 105 billion yuan in 2016, an increase of 10.52 percent over the previous year.
According to HDM system data, sales of anti-tumor and immunomodulant drugs in key urban public hospitals in China reached 17.684 billion yuan in the First-3 quarter of 2016, and are forecast to reach 23.6 billion yuan for the whole of 2016, up 9.07 percent from the previous year, with anti-tumor drugs accounting for nearly 60 percent of the total. Among them, the breast cancer drug TOP 5 is yew alcohol, dositamine, capertabin, qurto bead monoanti and bright propylene, accounting for 56.37 percent.: TOP 3 manufacturers account for 85%
Yew alcohol is a broad-spectrum anti-tumor drug, its unique micro-tube stabilization effect is widely used in a variety of common malignancies chemotherapy. The drug is a "double-edged sword" that can cause allergic reactions, toxic kidney damage, neurotoxicity and adverse effects on cardiovascular toxicity under its compound solution, thus causing new harm to patients. In order to better play the anti-cancer effect of yew alcohol, people have made in-depth exploration of its new dosage form, yew alcohol lipid drugs came out, in the treatment has made a breakthrough.
yew alcohol lipids have high safety, good tolerance and passive targeting characteristics of tumor tissue and lymphatic tissue compared to traditional yew alcohol preparations, yew alcohol lipids are 2 to 23 times higher than the distribution of free yew alcohol. Passive targeting is the basic characteristic of intravenous drugation of lipids. These properties make yew alcohol lipids naturally have the advantage of anti-lymph node metastasis, but also reduce their toxic effect on the heart, kidneys, but more importantly, yew alcohol lipids and tumor-targeted effects.
compared with traditional yew alcohol preparations, yew alcohol lipids are distributed quickly and eliminated slowly, which can maintain effective blood drug concentration in the body for a long time. In particular, the concentration of yew alcohol lipids in tumor tissue and lymph nodes is higher, with stronger anti-tumor efficacy and anti-lymphatic metastasis.
according to HDM system data, in the first three quarters of 2016, the sales amount of yew alcohol in key cities in China reached 1.015 billion yuan, and the total amount of yew alcohol used in 2016 is forecast to be 1.354 billion yuan, an increase of 9.96 percent over the previous year. TOP 3 manufacturers are: Green Leaf Cisco for 60.73 percent, Fessenyuscabi for 14.17 percent, Andersch/Corden for 10.49 percent.Dositas: Docetaxel
Docetaxel is a micro-tube antidote inhibitor (Docetaxel, polyene yew alcohol), a yew-based compound first developed by the French company Ronaplank Lean for the treatment of advanced breast and non-small cell lung cancer. Phase II clinical trials conducted at the M.D. Anderson Cancer Center in the United States have found that dossyla has better results for patients with advanced ovarian cancer who fail to apply cisplatin and carabenium. Moreover, Dorsey was significantly active in solid tumors such as prostate cancer, pancreatic cancer, soft tissue tumor, head and neck cancer, stomach cancer, esophageal cancer, etc.
has been listed in the United States, Japan and other more than 80 countries, in 1996 into China began clinical verification after listing. Jiangsu Hengrui has been developed in China has been approved for the market, at present, Hengrui's Dossy Tasi race in the hospital sales have exceeded imported drugs, become the largest sales of merchants.
According to HDM system data, in the first three quarters of 2016, the sales amount of public hospitals in key cities in China reached 675 million yuan, and the total amount of dossy drug use in 2016 is forecast to reach 899 million yuan, an increase of 2.79% year-on-year, far higher than similar varieties. Although the total sales of Dorsey race lag behind the yew alcohol, but the rapid growth rate, catch up with yew alcohol has become the first of its kind in the drug. In 2016, the top 5 manufacturers of dossyta top 5 in key cities in China were: Jiangsu Hengrui accounted for 40.72 percent, Sanofi for 29.74 percent, Shandong Qilu for 15.56 percent, Shenzhen Wanle for 8.39 percent, and Osaikang for 2.04 percent.Kapetabin: Roche's share of 70%
Shanghai Roche Capertabin tablets have entered the national health insurance drug list, the product is named Hiroda, Capertabin tablets are colorectal cancer, breast cancer combined chemotherapy and metastatic stomach cancer first-line treatment drugs.
normal cells and tumor cells can metabolize 5-FU into 5-fluorine-2-deoxyuric acid monophosphate (FdUMP) and 5-fluorourucleotide triphosphate (FUTP). Metabolites act on cellular tissues through two different mechanisms. Studies have shown that carpedabin has a fracture effect on human blood lymphocytes outside the body.
Kapatebin is the preferred single-use fluorine first-line chemotherapy drug for patients with metastatic colorectal cancer, and capedabin has a better lifetime than 5-FU/LV single-drug chemotherapy when combined with other drugs.
According to HDM system data, in the first three quarters of 2016, the domestic key urban public hospitals Capertabin sales amounted to 458 million yuan, the forecast for the full year 2016 public hospitals Capedabin sales amounted to 611 million yuan, an increase of 13.66 percent year-on-year, Capertabin can be combined with dosi yew alcohol for the treatment of chemotherapy failure of the treatment of cyclocyclin. In 2016, Roche accounted for 72.64 percent, Jiangsu Hengrui accounted for 10.81 percent, Qilu Pharmaceuticals accounted for 9.15 percent and Zhengda Tianqing accounted for 7.40 percent, showing a higher concentration.Quto Beads Monoantigen: Herceptin Exclusive Domestic Market
Curto Pearl Single Resistance was developed by Genentek Corporation of the United States and was approved by the FDA for clinical use on September 25, 1998, with the product named Herceptin. Roche acquired Genente, which is already Roche's single-drug unit. Compared with ordinary radiotherapy, chemotherapy and hormone therapy for breast cancer, the targeted killing of malignant tumor cells can be achieved through gene selection without affecting the survival of normal tissue cells in the human body.
is a recombinant DNA-derived humanized monoclonal antibody, which is a representative anti-tumor targeted antibody drug. The drug can selectively act on the outer cell of human skin growth factor-2, bind to its specific binding, affect the transmission of growth signals, and promote the intrinsic degradation of the protein, attack and kill tumor cells by aggregation of immune cells, clinically used in the treatment of advanced breast cancer. Currently, the European Union has approved Hersatin and dositamine as a first-line treatment for metastasis breast cancer that is positive for human skin growth factor 2 (HER2).
2002, Quto Zhu single resistance has been introduced into China's hospital market, with the commodity name Hessetin listed. At present, the domestic quto bead single anti-market by Hessetin exclusive.
According to HDM system data, in the first three quarters of 2016, the amount of anti-drug treatment in key urban public hospitals in China reached 441 million yuan, and the amount of anti-drug use in key urban public hospitals in China is forecast to reach 588 million yuan in 2016, an increase of 11.07 percent over the previous year. Hessetin drug toxicity is low, the therapeutic effect is obvious, the survival time is extended, which is of positive significance to improve the quality of life of patients with advanced cancer, and is the driving force for the growth of the anti-tumor monoanti-anti-market. : Three-legged stand-up pattern stabilized
Japan's Takeda is the world's main manufacturer of bright propylene relin, the commodity name Lupron, accounting for about half of the global market. It is reported that Takeda and Abbott co-founded TAP pharmaceutical company's patent expired in 2004. Tapp, which has been working with the two companies for 33 years, also expires in 2010, and Tap's bright proprin is run by Abbott, as well as Astellas, Sanofi-Avant, Orion, MediGene and OLT, which also sell bright propylene. In the past two years, in the situation of rising level of medical consumption, Liang Proprilin has gradually been accepted by domestic doctors and patients.
, ruilin polypeptide drugs are still occupied by foreign and joint ventures, higher prices make domestic patients unable to afford, thus restricting market development. With the improvement of the national health care system, this situation is expected to be improved. LHRH similars are not only used in the treatment of breast cancer, but also for prostate cancer and endometriosis. From the overall market point of view, the sales of this class of drugs increased year by year. With the increase of breast cancer incidence and the improvement of people's knowledge of breast cancer prevention, the market for breast cancer endocrine therapy drugs will continue to expand. Anti-estrogen and aromatase inhibitors dominate breast cancer endocrine therapy, especially aromatase inhibitors have grown rapidly in recent years and have become a hot spot in this field.
is the first drug among the prescription drugs of Ruilin in public hospitals in key cities in China, and it is also the highest growth rate. This class of peptide drugs is generally in small doses but require long-term administration, which provides an opportunity for innovative dosage forms. Takeda Pharmaceutical Industry Co., d'a.m. is a late last century in China into the clinical drug, the commodity is called tannatong. Subsequently, the original pharmaceutical plant developed a slow-release micro-ball technology, the technology is to wrap the drug in the micro-ball carrier, through subsuter or muscle administration, so that the drug slowly released, change the process of transport in the body, extend the action time. In 2009, Beijing Boente Pharmaceuticals, Shanghai Lizhu Pharmaceuticals' bright propylene relin injection with slow-release micro-ball was approved for the market.
According to HDM system data, in the first three quarters of 2016, the amount of drugs used in public hospitals in key cities in China reached 296 million yuan, and the amount of drugs used in public hospitals in cities in 2016 is forecast to reach 394 million yuan, an increase of 29.74 percent over the previous year. TOP 3 manufacturers are: Tianjin Takeda accounted for 53.37 percent, Beijing Boente Pharmaceuticals accounted for 23.68 percent, Shanghai Lizhu accounted for 22.95 percent. Basically formed a domestic bright propylene relin drug market three-legged pattern. (Medical Economics)